Developmental Funds

发展基金

基本信息

批准号：
10413083
负责人：
ROBERT S. MANNEL
金额：
$ 26.55万
依托单位：
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-05-01 至 2023-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10413083
关键词：
Address Award Biometry Cancer Center Cancer Center Support Grant Clinical Cancer Center Clinical Investigator Clinical Sciences Cytometry Development Direct Costs Emerging Technologies Ensure Evaluation Extramural Activities Foundations Funding Funding Mechanisms Goals Grant Growth Health Technology Investments Leadership Medical Research Mission Molecular Biology Monitor Oklahoma Pathology Peer Review Pilot Projects Play Publications Research Research Design Research Infrastructure Research Personnel Research Priority Resource Allocation Resource Sharing Rest Role Science Scientific Advances and Accomplishments Secure Services Source Strategic Planning Structure Therapeutic Tissues Underserved Population anticancer research base cancer health disparity cancer research center director drug discovery effectiveness evaluation effectiveness outcome innovation interdisciplinary collaboration mHealth new technology patient derived xenograft model personalized cancer therapy pre-clinical programs recruit translational cancer research

项目摘要

DEVELOPMENTAL FUNDS – ABSTRACT Developmental funds from institutional, state and philanthropic sources have been critically important in the growth of the Stephenson Cancer Center (SCC) since its inception. Over the past five years, the SCC has utilized developmental funds to advance the following key research priorities defined in the SCC's 2012-2016 Strategic Plan: 1) stimulating transdisciplinary and collaborative science within the SCC's programs; 2) advancing scientific findings through the development pipeline into NCTN and other trials; 3) conducting research to address cancer health disparities among underserved populations in Oklahoma; 4) supporting early-stage clinical investigators who are actively involved in the SCC's clinical science effort; and 5) investing in new emerging technologies and technical services to support programmatically aligned cancer research at the SCC. All decisions concerning the allocation of developmental funds ultimately rest with the SCC Director, who meets with his senior leadership team biweekly to discuss new research opportunities and potential allocation of resources for intramural grants, recruitment, and investments in new technologies. Intramural pilot grants supported by developmental funds have played a major role in advancing the SCC's mission and goals, providing the means for the SCC to pursue new research opportunities and achieve broad strategic objectives as well as providing the means for program leaders to achieve targeted scientific objectives. The SCC has strategically utilized developmental funds through competitively awarded pilot project and directed-funding mechanisms, including a major team-based award mechanism to support multi-PI projects with high potential of leading to PPG submissions, to stimulate research and enhance transdisciplinary collaborations. Over the past five years (CY2012-2016), the SCC has awarded 59 pilot grants, with a total award amount of $3,910,492. To date, these grants have resulted in 106 peer-reviewed publications and $28,227,492 (total, direct cost) in extramural sponsored research funding (as of 4/15/17). Developmental funds have allowed the SCC to establish and enhance research infrastructure, including the Biostatistics and Research Design, Tissue Pathology, Molecular Biology and Cytometry Research, and Mobile Health Technology Shared Resources. For the upcoming five-year period, the SCC is requesting developmental funds to support the growth of a Patient-Derived Xenograft and Preclinical Therapeutics (PDX- PCT) Core housed at the Oklahoma Medical Research Foundation (OMRF), the SCC's proposed consortium partner. Established in 2015, this Core provides SCC investigators and other campus investigators with high- quality services for basic and translational cancer research, drug discovery and personalized cancer therapy. The goal is to develop the PDX-PCT Core into a formal shared resource within a five-year timeframe.

发展基金 - 摘要机构，州和慈善来源的发展基金在斯蒂芬森癌症中心（SCC）成立以来的生长。在过去的五年中，SCC有利用发展基金来提高SCC 2012-2016中定义的以下关键研究优先级战略计划：1）在SCC计划中刺激跨学科和协作科学； 2）通过发展管道将科学发现推进NCTN和其他试验； 3）进行研究俄克拉荷马州服务不足人群中癌症健康分布的研究； 4）支持积极参与SCC的临床科学工作的早期临床研究人员； 5）投资在新的新兴技术和技术服务中，以支持编程的癌症研究 SCC。有关分配发展基金的所有决定，最终都会取决于SCC董事，他每两周与他的高级领导团队会面，讨论新的研究机会和潜力为新技术的壁内赠款，招聘和投资分配资源。由发展基金支持的壁内飞行员赠款在推进SCC方面发挥了重要作用任务和目标，为SCC提供购买新研究机会并实现广泛的手段战略目标以及为计划领导者提供目标科学的手段目标。 SCC通过竞争性授予的试点项目战略性地利用了发展资金和指导资助机制，包括一种基于团队的主要奖励机制，以支持Multi-Pi 潜力很高的项目导致PPG提交，以刺激研究并增强跨学科协作。在过去的五年中（CY2012-2016），SCC已授予59个飞行员赠款，总共奖励金额为$ 3,910,492。迄今为止，这些赠款已导致106个同行评审的出版物， $ 28,227,492（截至4/15/17）的校外赞助资金中的28,227,492美元（总成本）。发展基金使SCC能够建立和增强研究基础设施，包括生物统计学和研究设计，组织病理学，分子生物学和细胞术研究以及移动卫生技术共享资源。在接下来的五年期间，SCC要求发展基金以支持患者衍生的异种移植和临床前疗法的增长（PDX- pct）核心位于俄克拉荷马州医学研究基金会（OMRF），SCC的拟议财团伙伴。该核心成立于2015年，为SCC调查人员和其他校园调查员提供了高级基础和翻译癌症研究，药物发现和个性化癌症疗法的质量服务。目的是将PDX-PCT核心开发为五年的时间范围内的正式共享资源。